Project description:Experiment was designed to study the effect of Hippo pathway on osimertinib resistance in non-small cell lung cancer cell lines. The specific comparisons investigated were: PC-9: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE, EV DMSO treated vs EV osimertinib treated HCC827: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE,EV DMSO treated vs EV osimertinib treated HCC4006: NTC vs NF2 KO, EV vs YAP1 OE, EV vs WWTR1 OE, EV DMSO treated vs EV osimertinib treated
Project description:To profile the transcriptome of samples by “sample type (EV vs. Cell)”, “sex (Female vs. Male)”, and “treatment (0 vs. 120 vs 320 mg / dL)”. We performed gene expression profiling analysis using data obtained from RNA-seq of 18 EV samples and 18 cell samples in different treatment groups and sex.
Project description:Background Distinguishing benign from malignant pancreaticobiliary disease is challenging because of the absence of reliable biomarkers. Circulating extracellular vesicles (EVs) have emerged as functional mediators between cells. Their cargos, including microRNAs (miRNAs), are increasingly acknowledged as an important source of potential biomarkers. This multicentric, prospective study aimed to establish a diagnostic plasma EV-derived miRNA signature to discriminate pancreatic ductal adenocarcinoma (PDAC) from benign pancreaticobiliary disease. Methods Plasma EVs were isolated using size exclusion chromatography (SEC) and characterised using nanoparticle tracking analysis, electron microscopy and Western blotting. EV-RNAs underwent small RNA sequencing to discover differentially expressed markers for PDAC (n = 10 benign vs. 10 PDAC). Candidate EV-miRNAs were then validated in a cohort of 61 patients (n = 31 benign vs. 30 PDAC) by RT-qPCR. Logistic regression and optimal thresholds (Youden Index) were used to develop an EV-miR-200 family model to detect cancer. This model was tested in an independent cohort of 95 patients (n = 30 benign, 33 PDAC, and 32 cholangiocarcinoma). Results Small RNA sequencing and RT-qPCR showed that EV-miR-200 family members were significantly overexpressed in PDAC vs. benign disease. Combined expression of the EV-miR-200 family showed an AUC of 0.823. In an independent validation cohort, application of this model showed a sensitivity, specificity and AUC of 100%, 88%, and 0.97, respectively, for diagnosing PDAC.
Project description:After mapping to transcriptome using bowtie2 and peak calling by RNA peak caller (cfPeak), count matrix was created by merge 3 pairs of samples. EV-sorting small RNA sites in normal human plasma total RNA-seq were annotated by comparing differentially expressed peaks (EV vs. EV-depleted Plasma).
Project description:Forkhead BoxO (FoxO) transcription factors expressed in adult skeletal muscle promote muscle atrophy during various catabolic conditions. We have identified the genome wide target genes and biological networks regulated by FoxO in skeletal muscle during Colon-26 (C-26) cancer cachexia. In this dataset, we include the expression data obtained from the tibialis anterior muscles of control and severely cachectic Colon-26 mice in which FoxO-dependent transcription was either intact (AAV9-EV) or inhibited (AAV9-d.n.FoxO). These data were used to obtain 543 FoxO target genes during cancer. These target genes were identified as those genes whose expression was both differentially regulated in skeletal muscle in response to cancer (control AAV9-EV vs. C26 AAV9-EV), and differentially regulated in the presence of d.n.FoxO (C26 AAV9-EV vs. C26 AAV9-d.n.FoxO).
Project description:Secretome containing extracellular vesicles (EV) seem to mediate the benefits of cell therapy for ischemic heart failure. Our project has the objective of comparing the secretome containing extracellular vesicles (EV) from cardiac progenitor cells (EV-CPC) vs the secretome containing EV from Fibroblasts (EV-FB) in order to stablish a protein cartography of EV-CPC and the biological pathways that they are involved. seem to mediate the benefits of cell therapy for ischemic heart failure. Our project has the objective of comparing the secretome containing extracellular vesicles (EV) from cardiac progenitor cells (EV-CPC) vs the secretome containing EV from Fibroblasts (EV-FB) in order to stablish a protein cartography of EV-CPC and the biological pathways that they are involved.